Navigation Links
DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
Date:3/31/2009

PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, today announced its financial results for 2008.

DOR's revenues for 2008 were approximately $2.3 million compared to $1.3 million in 2007. The increase was due primarily to progress with DOR's September 2006 NIH grant and the resulting achievement of certain research and development milestones with our subcontractors.

DOR's net loss for 2008 was approximately $3.4 million, or $0.03 per share, compared to $6.2 million, or $0.07 per share, for 2007. This decrease in net loss is primarily attributed to lower research and development costs associated with Food and Drug Administration (FDA) and European regulatory matters as well as a reduction in general and administrative expenses. Research and development expenses for 2008 were approximately $1.6 million, compared with $3.1 million for 2007. General and administrative expenses for 2008 were approximately $1.9 million, compared with $2.9 million for 2007.

"2009 is off to a strong start for DOR," stated Christopher J. Schaber, PhD, President and CEO of DOR. "To start the year off, we announced FDA clearance under its Special Protocol Assessment (SPA) procedure to begin our confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD. This, in part, has enabled us to shore up our balance sheet significantly as a result of our partnership with Sigma-Tau Pharmaceuticals. We now have an experienced partner in the HSC transplant arena, regulatory clarity with regard to the Phase 3 development of orBec(R), and a relatively clean capital structure. We have also begun adding key personnel to execute new clinical trials in GI GVHD and radiation enteritis. We are looking forward to initiating the confirmatory Phase 3 clinical trial and are optimistic that 2009 will be a year of substa
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Heroic worldwide conservation efforts have made great strides in ... in China, there are over 65 giant panda reserves ... But despite these efforts, just 1596 pandas remain in ... and zoos hope to save the panda by improving ... to the wild. Just how are these high-profile programs ...
(Date:7/23/2014)... , July 23, 2014  AuraSense Therapeutics, ... as gene regulatory and immunotherapeutic agents, announced ... joined AuraSense Therapeutics, executive leadership team as ... Prior to joining AuraSense Therapeutics, Mr. ... Financial Officer of Cellular Dynamics International Inc., ...
(Date:7/23/2014)... SAN ANTONIO , 23 de julio de ... ADBI (ADBI o la Compañía) ha anunciado hoy ... Akron (ABIA o el Instituto), ... de ADBI, un dispositivo de terapia de señal ...   El Instituto, que tiene una ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
Breaking Biology Technology:AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 2ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 3ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 4ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 5ADB International Group Inc. anuncia una asociación con Austen BioInnovation Institute 6BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... has successfully completed patient enrolment in its multi-centre Phase ... REOLYSIN(R) in patients with various sarcomas that have metastasized ... been enrolled in the trial. , "We are extremely ...
... /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading ... announced financial and operational results for the first quarter, ... to obtain the results from MAESTRO-01, the first of ... secondary progressive multiple sclerosis, in the second half of ...
... Sky One Medical,Inc. ("China Sky One Medical" or "the ... pharmaceutical company producing over-the-counter drugs in,the People,s Republic of ... call at 10:00 a.m. Eastern Daylight Time (EDT) on ... fiscal year 2009 financial results. , ...
Cached Biology Technology:Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 2Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study 3BioMS Medical Announces First quarter 2009 results 2BioMS Medical Announces First quarter 2009 results 3BioMS Medical Announces First quarter 2009 results 4BioMS Medical Announces First quarter 2009 results 5BioMS Medical Announces First quarter 2009 results 6BioMS Medical Announces First quarter 2009 results 7BioMS Medical Announces First quarter 2009 results 8BioMS Medical Announces First quarter 2009 results 9China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3
(Date:7/24/2014)... which life arose have been maintained in our cells today ... Research published today in the Journal of Biological Chemistry ... also in animals still perform ancient reactions thought to have ... billion years ago. , The primordial soup theory suggests that ... of the combination of metals, gases from the atmosphere and ...
(Date:7/24/2014)... in mid-July 2014, as the annual fire season continues ... of increased temperatures, are heavily sprinkled across the Congo ... (northeast), and Zambia (southeast). Thick gray smoke rises from ... in the Democratic Republic of the Congo, strong winds ... season is an annual event in this region, as ...
(Date:7/24/2014)... new drug that successfully treated lupus in mice, a biomedical ... grant to expand his research to a new version of ... of autoimmune diseases., Chandra Mohan, Hugh Roy and Lillie Cranz ... a study in Arthritis Research & Therapy outlining the use ... and reduced the number of cases of lupus-related kidney disease., ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... new hope for controlling the devastating impact of Ebola ... ape die-offs first circulated widely in 2003, sceptics have ... was even the cause. The new study, led by ... doubts because it was conducted in a closely monitored ...
... have discovered that a specific human protein is essential for ... that when HIV inserts itself into a chromosome, a key ... requires a specific protein -- LEDGF/p75 (p75). This protein forms ... If the connection can be disrupted in the future, it ...
... and using the latest in imaging software and machinery, also ... have developed a fast and accurate means of tracking blood ... arteries. Researchers say it took them less than half ... used to find early warning of vessels more likely to ...
Cached Biology News:Ebola-outbreak kills 5000 gorillas 2Ebola-outbreak kills 5000 gorillas 3Mayo researchers discover HIV dependence on a human protein 2Fast test for low blood flow in dogs detects early heart trouble 2Fast test for low blood flow in dogs detects early heart trouble 3Fast test for low blood flow in dogs detects early heart trouble 4
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... to ThPok ( Abpromise for all tested ... conjugated to KLH derived from within residues 500 ... the amino acid sequence is proprietary) ... Entrez Gene ID: 51043 ...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: